title: [Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].
authors.affiliation: Institut für Pathologie, Charité - Universitätsmedizin Berlin,Campus Mitte, Charitéplatz 1, 10117, Berlin, Deutschland. manfred.dietel@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Dietel
authors.forename: A
authors.initials: A
authors.lastname: Tannapfel
authors.forename: G
authors.initials: G
authors.lastname: Baretton
authors.forename: H
authors.initials: H
authors.lastname: Kreipe
authors.forename: M
authors.initials: M
authors.lastname: Kloor
authors.forename: H
authors.initials: H
authors.lastname: Gabbert
authors.forename: T
authors.initials: T
authors.lastname: Kirchner
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D004252:DNA Mutational Analysis; D006801:Humans; D009367:Neoplasm Staging; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077544:Panitumumab; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins